SI1612203T1 - Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida - Google Patents

Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida

Info

Publication number
SI1612203T1
SI1612203T1 SI200430461T SI200430461T SI1612203T1 SI 1612203 T1 SI1612203 T1 SI 1612203T1 SI 200430461 T SI200430461 T SI 200430461T SI 200430461 T SI200430461 T SI 200430461T SI 1612203 T1 SI1612203 T1 SI 1612203T1
Authority
SI
Slovenia
Prior art keywords
methylpropyl
dimethylamino
ethyl
crystalline forms
phenol hydrochloride
Prior art date
Application number
SI200430461T
Other languages
English (en)
Inventor
Andreas Dr Fischer
Helmut Dr Buschmann
Michael Dr Gruss
Dagmar Lischke
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34925507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1612203(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of SI1612203T1 publication Critical patent/SI1612203T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
SI200430461T 2004-06-28 2004-06-28 Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida SI1612203T1 (sl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04015091A EP1612203B1 (en) 2004-06-28 2004-06-28 Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

Publications (1)

Publication Number Publication Date
SI1612203T1 true SI1612203T1 (sl) 2007-12-31

Family

ID=34925507

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200430461T SI1612203T1 (sl) 2004-06-28 2004-06-28 Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida
SI200531252T SI1799633T1 (sl) 2004-06-28 2005-06-27 Kristalinične oblike hidroklorida (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenola za uporabo kot aktivna sestavina v farmacevtskih sestavkih

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200531252T SI1799633T1 (sl) 2004-06-28 2005-06-27 Kristalinične oblike hidroklorida (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenola za uporabo kot aktivna sestavina v farmacevtskih sestavkih

Country Status (27)

Country Link
US (16) US20070213405A1 (sl)
EP (2) EP1612203B1 (sl)
JP (1) JP4990764B2 (sl)
KR (1) KR101096501B1 (sl)
CN (1) CN1997621B (sl)
AR (2) AR049949A1 (sl)
AT (2) ATE368639T1 (sl)
AU (1) AU2005256512B2 (sl)
BR (2) BR122018014454B8 (sl)
CA (1) CA2572147C (sl)
CY (2) CY1106929T1 (sl)
DE (2) DE602004007905T2 (sl)
DK (2) DK1612203T3 (sl)
EC (1) ECSP17046065A (sl)
ES (2) ES2291780T3 (sl)
HR (1) HRP20110050T8 (sl)
IL (1) IL180373A (sl)
MX (1) MXPA06014741A (sl)
NO (3) NO338605B1 (sl)
NZ (1) NZ551605A (sl)
PE (1) PE20060372A1 (sl)
PL (2) PL1612203T3 (sl)
PT (2) PT1612203E (sl)
RU (1) RU2423345C2 (sl)
SI (2) SI1612203T1 (sl)
WO (1) WO2006000441A2 (sl)
ZA (1) ZA200700774B (sl)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
ES2291780T3 (es) * 2004-06-28 2008-03-01 Grunenthal Gmbh Formas cristalinas del clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)fenol.
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
DE102007019417A1 (de) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
PT3173400T (pt) * 2007-12-07 2019-12-13 Gruenenthal Gmbh Modificações cristalinas de (1r, 2r)-3-(3-dimetilamino-1- etil-2-metil-propil)-fenol
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
EP2273983B1 (en) 2008-05-09 2016-07-20 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
ES2560210T3 (es) 2009-07-22 2016-02-17 Grünenthal GmbH Forma de dosificación resistente a la manipulación para opiádes sensibles a la oxidación
JP5667183B2 (ja) 2009-07-22 2015-02-12 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 加熱溶融押出成型した制御放出性投与剤型
US8288592B2 (en) * 2009-09-22 2012-10-16 Actavis Group Ptc Ehf Solid state forms of tapentadol salts
US20130116333A1 (en) 2010-05-05 2013-05-09 Ratiopharm Gmbh Solid tapentadol in non-crystalline form
PL3650439T3 (pl) 2010-07-23 2021-06-28 Grünenthal GmbH Sole lub kokryształy 3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenolu
RU2604676C2 (ru) 2010-09-02 2016-12-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
KR20130137627A (ko) 2010-09-02 2013-12-17 그뤼넨탈 게엠베하 음이온성 중합체를 포함하는 내변조성 투여형
WO2012051246A1 (en) 2010-10-12 2012-04-19 Ratiopharm Gmbh Tapentadol hydrobromide and crystalline forms thereof
CN103501774A (zh) 2011-03-04 2014-01-08 格吕伦塔尔有限公司 含有他喷他多的半固体含水药用组合物
JP2014510067A (ja) * 2011-03-04 2014-04-24 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口的投与
KR102051800B1 (ko) 2011-03-04 2019-12-04 그뤼넨탈 게엠베하 경구 투여를 위한 타펜타돌의 수성 약제학적 제형
AR087359A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
WO2013017234A1 (en) 2011-07-29 2013-02-07 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
WO2013111161A2 (en) * 2012-01-10 2013-08-01 Msn Laboratories Limited Process for the preparation of 3-aryl-2-methyl-propanamine derivatives and polymorphs thereof
WO2013120466A1 (en) 2012-02-17 2013-08-22 Zentiva, K.S. A new solid form of tapentadol and a method of its preparation
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
ES2692944T3 (es) 2012-04-18 2018-12-05 Grünenthal GmbH Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CZ304576B6 (cs) * 2012-07-24 2014-07-16 Zentiva, K.S. Oxalát TAPENTADOLU a způsob jeho přípravy
CN102924303B (zh) * 2012-10-31 2013-11-20 合肥市新星医药化工有限公司 盐酸他喷他多晶型c及其制备方法和应用
EP3003283A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
EA032465B1 (ru) 2013-07-12 2019-05-31 Грюненталь Гмбх Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
US9599565B1 (en) * 2013-10-02 2017-03-21 Ondax, Inc. Identification and analysis of materials and molecular structures
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
CZ307492B6 (cs) 2014-02-04 2018-10-17 Zentiva, K.S. Pevná forma maleátu tapentadolu a způsob její přípravy
GB2523089A (en) * 2014-02-12 2015-08-19 Azad Pharmaceutical Ingredients Ag Stable polymorph form B of tapentadol hydrochloride
CN106572980A (zh) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 包含他喷他多的防篡改即释胶囊制剂
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
HUE042612T2 (hu) 2015-03-27 2019-07-29 Gruenenthal Gmbh Parenterális alkalmazású stabil Tapentadol készítmény
KR20170139158A (ko) 2015-04-24 2017-12-18 그뤼넨탈 게엠베하 즉시 방출되고 용매 추출 방지된 변조 방지된 투여 형태
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
DK3445742T3 (da) 2016-04-19 2020-02-24 Ratiopharm Gmbh Krystallin tapentadolphosphat
PE20190908A1 (es) 2016-09-23 2019-06-26 Gruenenthal Chemie Formulacion estable para la administracion parenteral de tapentadol
EP3585370A1 (en) 2017-02-23 2020-01-01 Grünenthal GmbH Tapentadol as local anesthetic
US11492342B2 (en) 2020-11-03 2022-11-08 Landos Biopharma, Inc. Crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridin-2yl)methanone)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
NZ334132A (en) * 1996-08-14 2000-06-23 G Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide
EP1330427A1 (en) * 2000-10-31 2003-07-30 Ciba SC Holding AG Crystalline forms of venlafaxine hydrochloride
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
IL160681A0 (en) * 2001-09-13 2004-08-31 Kissei Pharmaceutical Crystals of hydroxynorephedrine derivatives
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
ES2291780T3 (es) * 2004-06-28 2008-03-01 Grunenthal Gmbh Formas cristalinas del clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)fenol.

Also Published As

Publication number Publication date
HRP20110050T1 (hr) 2011-02-28
SI1799633T1 (sl) 2011-05-31
DK1799633T3 (da) 2011-03-28
AU2005256512B2 (en) 2011-05-19
US20140296346A1 (en) 2014-10-02
CY1106929T1 (el) 2012-09-26
PE20060372A1 (es) 2006-05-08
BRPI0512792A (pt) 2008-04-08
US20210261492A1 (en) 2021-08-26
US20140011886A1 (en) 2014-01-09
AU2005256512A1 (en) 2006-01-05
CA2572147A1 (en) 2006-01-05
DE602005026031D1 (de) 2011-03-03
NZ551605A (en) 2010-01-29
US20120302643A1 (en) 2012-11-29
ZA200700774B (en) 2008-09-25
ES2359504T3 (es) 2011-05-24
US20110294898A1 (en) 2011-12-01
BR122018014454B1 (pt) 2019-09-03
BR122018014454B8 (pt) 2021-07-27
US20170166515A1 (en) 2017-06-15
JP2008504326A (ja) 2008-02-14
WO2006000441A2 (en) 2006-01-05
EP1799633A2 (en) 2007-06-27
IL180373A (en) 2012-05-31
ECSP17046065A (es) 2018-11-30
KR101096501B1 (ko) 2011-12-20
NO338605B1 (no) 2016-09-12
WO2006000441A3 (en) 2006-05-04
PT1799633E (pt) 2011-03-07
CA2572147C (en) 2012-10-30
MXPA06014741A (es) 2007-02-12
HRP20110050T8 (en) 2011-03-31
IL180373A0 (en) 2007-06-03
US20090186947A1 (en) 2009-07-23
RU2423345C2 (ru) 2011-07-10
ES2291780T3 (es) 2008-03-01
US7994364B2 (en) 2011-08-09
CY1111530T1 (el) 2015-08-05
US20070213405A1 (en) 2007-09-13
PL1612203T3 (pl) 2007-12-31
NO20070162L (no) 2007-01-24
AR116052A2 (es) 2021-03-25
EP1612203B1 (en) 2007-08-01
DE602004007905D1 (de) 2007-09-13
US20230174458A1 (en) 2023-06-08
DK1612203T3 (da) 2007-12-03
US20160122287A1 (en) 2016-05-05
JP4990764B2 (ja) 2012-08-01
US20200385334A1 (en) 2020-12-10
AR049949A1 (es) 2006-09-20
EP1612203A1 (en) 2006-01-04
PL1799633T3 (pl) 2011-06-30
CN1997621B (zh) 2011-06-15
KR20070039929A (ko) 2007-04-13
EP1799633B1 (en) 2011-01-19
NO343922B1 (no) 2019-07-08
DE602004007905T2 (de) 2008-05-08
US20190062263A1 (en) 2019-02-28
CN1997621A (zh) 2007-07-11
RU2007103297A (ru) 2008-08-10
NO20160914A1 (no) 2007-01-24
ATE368639T1 (de) 2007-08-15
NO341239B1 (no) 2017-09-25
US20100160447A1 (en) 2010-06-24
US20180230082A1 (en) 2018-08-16
NO20171103A1 (no) 2007-01-24
US20180029976A1 (en) 2018-02-01
ATE496021T1 (de) 2011-02-15
PT1612203E (pt) 2007-08-20
US20200102261A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
IL180373A0 (en) Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
IL255201A0 (en) Process for the preparation of (r2, 1r)-3-3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
DK1786403T3 (da) Mod misbrug sikret, oral indgivelsesform indeholdende (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
IL237478A0 (en) Crystalline changes of (32)-3-(r1,r-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
IL186220A0 (en) Processes for the preparation of atomoxetine hydrochloride
IL179328A0 (en) Levalbuterol hydrochloride polymorph b
IL187735A0 (en) 2-(n-nethyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
EP1778208A4 (en) VENLAFAXINE-HYDROCHLORIDE-CONTAINING CAPSULES WITH EXTENDED RELEASE
EP1802575A4 (en) POLYMORPH OF N, N-DIETHYL-4- (3-FLUORPHENYLPIPERIDIN-4-YLIDENETHYL) -BENZAMIDE HYDROCHLORIDE SALT